NCT03939182View on ClinicalTrials.gov

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 29, 2019

Primary Completion Date

April 22, 2025

Study Completion Date

April 22, 2025

Conditions
Diffuse Large B-cell LymphomaMantle Cell Lymphoma
Interventions
DRUG

Abexinostat

Two doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.

DRUG

Ibrutinib

Ibrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

18103

Lehigh Valley Health Network, Allentown

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

collaborator

Xynomic Pharmaceuticals, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03939182 - Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter